The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results